peptides athletes FAQ

Administer the missed dose as soon as you remember if fewer than three days have passed, then resume your regular schedule. TB-500's 10-day half-life means missing one injection reduces plasma levels but doesn't eliminate therapeutic effect entirely. If more than three days have passed, skip the missed dose and continue with the next scheduled administration. Doubling up causes no additional benefit and increases the risk of desensitization to the compound's effects over time.

Verify injection proximity to the injury site. BPC-157 acts locally through angiogenesis, and subcutaneous administration more than 2–3 cm from the affected tissue reduces therapeutic concentration at the target. Reassess dosing frequency: the four-hour half-life means once-daily administration leaves 16–20 hours with subtherapeutic plasma levels. Split the total daily dose into morning and evening injections. If using oral BPC-157, switch to injectable. Oral bioavailability is significantly lower due to gastric acid degradation of the peptide structure.

TB-500 addresses tissue repair through cell migration but doesn't directly modulate inflammatory cytokines or cortisol-to-testosterone ratios. Systemic fatigue during high-volume phases often reflects neuroendocrine dysregulation rather than tissue damage. Consider adding Thymalin to support immune function or a growth hormone secretagogue like MK 677 to elevate anabolic signaling. Alternatively, reassess training volume. If recovery demand exceeds even enhanced physiological capacity, the solution is deloading, not increased peptide dosing.

TB-500 at 2–5 mg twice weekly addresses systemic inflammation more effectively than site-specific peptides because its cellular migration mechanism works throughout the body rather than at a single injection point. Combine with periodized deloading (reducing training volume by 40–50% every 4th week) to allow tissue remodeling. Peptides accelerate repair, but they can't compensate for continuous mechanical stress that exceeds tissue adaptation capacity.

CJC-1295 with DAC (2 mg weekly) combined with Ipamorelin (200–300 mcg nightly before bed) optimizes the GH release pattern that supports overnight recovery without suppressing natural pulsatility. Administer Ipamorelin 30–60 minutes before sleep to align with the body's largest natural GH pulse, which occurs 60–90 minutes after sleep onset. Avoid dosing immediately post-workout. The endogenous GH surge from training (which peaks 15–30 minutes post-exercise) provides maximal benefit when unblocked by exogenous compounds.

Administer BPC-157 subcutaneously near the injury site at 250–500 mcg daily for 4–6 weeks, starting as soon as inflammation subsides (typically 3–5 days post-injury). The mechanism depends on vascularization of the damaged tissue, which peaks 7–14 days post-injury. Starting earlier won't improve outcomes, and starting later misses the angiogenic window when new vessel formation is most responsive to VEGF signaling.